The positive results from the Phase II clinical trial indicate that Lanifibranor has a favorable safety and tolerability profile, which is likely to boost investor confidence in Inventiva (IVA). The achievement of primary efficacy endpoint and multiple secondary metabolic endpoints further supports the potential of Lanifibranor in treating T2D and NAFLD patients, potentially leading to increased demand for the drug and a positive impact on IVA's stock price in the short term.